|
2025
|
Invention
|
Compositions comprising pharmaceutically acceptable salts and other derivatives of dual glp-1/amy... |
|
|
Invention
|
Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones.
D... |
|
|
Invention
|
Compositions comprising pharmaceutically acceptable salts and other derivatives of glucagon-like ... |
|
|
Invention
|
Compositions comprising pharmaceutically acceptable salts and other derivatives of an amylin anal... |
|
2024
|
Invention
|
Methods of using rary agonists for cancer treatment.
The invention discloses novel RAR gamma sel... |
|
|
Invention
|
Use of an rxr agonist in treating drug resistant her2+ cancers.
The present specification provid... |
|
|
Invention
|
Synthesis of tetrahydronaphthalenols and uses thereof.
Provided herein are compounds and synthet... |
|
|
Invention
|
Rxr agonist salt form, polymorphs thereof, and uses thereof. Provided herein are salt and solid f... |
|
2023
|
Invention
|
Methods of using rarγ agonists for cancer treatment. The invention discloses novel RAR gamma sele... |
|
|
Invention
|
Synthesis of tetrahydronaphthalenols and uses thereof. Provided herein are selective tetrahydrona... |
|
|
Invention
|
Synthesis of tetrahydronaphthalenols and uses thereof. Provided herein are compounds and syntheti... |
|
|
Invention
|
Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer.
Disclosed herein... |
|
|
Invention
|
Rxr agonist salt forms, polymorphs thereof, and uses thereof. Provided herein are salt and solid ... |
|
2022
|
Invention
|
Use of an rxr agonist and taxanes in treating her2+ cancers. The present specification provides i... |
|
|
Invention
|
+ cancers. The present specification provides combinations of active agents for the improved trea... |
|
|
Invention
|
Use of an rxr agonist and taxanes in treating her2+ cancers. + cancer. Thyroid hormone and other ... |
|
|
Invention
|
Use of an rxr agonist in treating drug resistant her2+ cancers. + cancers and associated methods ... |
|
|
Invention
|
Ionic liquid compositions. Provided herein are compositions or compounds comprising ionic liquids... |
|
|
Invention
|
Treatment of disease with esters of selective rxr agonists.
The present specification provides m... |
|
|
Invention
|
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effect... |
|
|
Invention
|
Ionic liquid formulations for treating inflammatory and autoimmune diseases. The present disclosu... |
|
|
Invention
|
Receptor subtype and function selective retinoid and rexinoid compounds in combination with immun... |
|
|
Invention
|
Autoimmune disorder treatment using rxr agonists. The present specification provides RXR agonist ... |
|
2021
|
Invention
|
Use of an rxr agonist in treating her2+ cancers.
The present specification provides combinations... |
|
|
Invention
|
Ionic liquid formulations for treating diabetes. Disclosed herein are ionic liquids and deep eute... |
|
|
Invention
|
Treatment of cancer with specific rxr agonists.
A method of treating cancer is disclosed compris... |
|
|
Invention
|
Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones. The pres... |
|
|
Invention
|
Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids.
P... |
|
2020
|
Invention
|
Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer. Disclosed herein ... |
|
|
Invention
|
Use of an rxr agonist in treating her2+ cancers. + cancers and associated methods of treatments. ... |
|
|
Invention
|
Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combin... |
|
|
Invention
|
Rar selective agonists in combination with immune modulators for cancer immunotherapy. Disclosed ... |
|
|
Invention
|
Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones.
The pres... |
|
|
Invention
|
Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones. Di... |
|
|
Invention
|
Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids. Pr... |
|
2019
|
Invention
|
Use of an rxr agonist in treating her2+ cancers. The present specification provides combinations ... |
